Maxime Ronot, Marco Dioguardi Burgio, Jules Gregory, Olivia Hentic, Marie-Pierre Vullierme, Philippe Ruszniewski, Magaly Zappa, Louis de Mestier
Neuroendocrine tumors (NETs) are relatively rare neoplasms displaying heterogeneous clinical behavior, ranging from indolent to aggressive forms. Patients diagnosed with NETs usually receive a varied array of treatments, including somatostatin analogs, locoregional treatments (ablation, intra-arterial therapy), cytotoxic chemotherapy, peptide receptor radionuclide therapy (PRRT), and targeted therapies. To maximize therapeutic efficacy while limiting toxicity (both physical and economic), there is a need for accurate and reliable tools to monitor disease evolution and progression and to assess the effectiveness of these treatments...
October 13, 2023: Best Practice & Research. Clinical Endocrinology & Metabolism